Related Experiment Video
Updated: Mar 22, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Genistein decreases basal hepatic cytochrome P450 1A1 protein expression and activity in Swiss Webster mice
Erik B Froyen1, Francene M Steinberg1
1Department of Nutrition and Graduate Group in Nutritional Biology, University of California, Davis, Davis, CA 95616, USA.
Abstract:
Soy consumption has been associated with risk reduction for chronic diseases such as cancer. One proposed mechanism for cancer prevention by soy is through decreasing cytochrome P450 1A1 (Cyp1a1) activity. However, it is not known with certainty which soy components modulate Cyp1a1, or the characteristics or mechanisms involved in the responses after short-term (<20 days) dietary treatment without concomitant carcinogen-mediated induction. Therefore, the objective was to test the hypothesis that physiologic concentrations of dietary genistein and/or daidzein will decrease basal hepatic Cyp1a1 protein expression and activity in male and female Swiss Webster mice via inhibiting the bindings of aryl hydrocarbon receptor (AhR)-AhR nuclear translocator (ARNT) and estrogen receptor-α to the Cyp1a1 promoter region xenobiotic response element. The mice were fed the AIN-93G diet supplemented with 1500 mg/kg of genistein or daidzein for up to 1 week. Genistein, but not daidzein, significantly decreased basal hepatic microsomal Cyp1a1 protein expression and activity. AhR protein expression was not altered. Molecular mechanisms were investigated in Hepa-1c1c7 cells treated with 5 μmol/L purified aglycones genistein, daidzein, or equol. Cells treated with genistein exhibited inhibitions in ARNT and estrogen receptor-α bindings to the Cyp1a1 promoter region. This study demonstrated that genistein consumption reduced constitutive hepatic Cyp1a1 protein expression and activity, thereby contributing to the understanding of how soy isoflavone aglycones modulate cytochrome P450 biotransformation enzymes.
Insights
Genistein, a soy isoflavone, reduces cytochrome P450 1A1 (Cyp1a1) activity by inhibiting key protein bindings. This finding clarifies how soy components may lower cancer risk through modulating metabolic enzymes.
Area of Science:
- Biochemistry
- Pharmacology
- Nutritional Science
Background:
- Soy consumption is linked to reduced chronic disease risk, potentially via decreased cytochrome P450 1A1 (Cyp1a1) activity.
- The specific soy components and mechanisms modulating Cyp1a1 activity, especially without carcinogen induction, remain unclear.
Purpose of the Study:
- To investigate if dietary genistein and/or daidzein decrease basal hepatic Cyp1a1 expression and activity.
- To elucidate the molecular mechanisms involving aryl hydrocarbon receptor (AhR)-ARNT and estrogen receptor-α binding to the Cyp1a1 promoter.
Main Methods:
- Mice were fed diets supplemented with genistein or daidzein for one week.
- Hepa-1c1c7 cells were treated with purified aglycones (genistein, daidzein, equol) to study molecular mechanisms.
Main Results:
- Genistein significantly decreased hepatic Cyp1a1 protein expression and activity in mice.
- Genistein inhibited ARNT and estrogen receptor-α binding to the Cyp1a1 promoter in cell studies.
- Daidzein did not significantly alter Cyp1a1 activity, and AhR protein expression remained unchanged.
Conclusions:
- Genistein consumption reduces constitutive hepatic Cyp1a1 expression and activity.
- This study contributes to understanding how soy isoflavones modulate cytochrome P450 biotransformation enzymes, potentially explaining cancer risk reduction.
- Genistein's mechanism involves inhibiting specific protein-DNA interactions at the Cyp1a1 promoter.
Related Concept Videos
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
In-vitro Mutagenesis

